• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

EANM 实践指南：分子放疗吸收剂量计算中的不确定性分析。

EANM practical guidance on uncertainty analysis for molecular radiotherapy absorbed dose calculations.

机构信息

The Royal Marsden NHS Foundation Trust & Institute of Cancer Research, Downs Road, Sutton, SM2 5PT, UK.

National Physical Laboratory, Teddington, TW11 0LW, UK.

出版信息

Eur J Nucl Med Mol Imaging. 2018 Dec;45(13):2456-2474. doi: 10.1007/s00259-018-4136-7. Epub 2018 Sep 14.

DOI:10.1007/s00259-018-4136-7
PMID:30218316
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6208822/
Abstract

A framework is proposed for modelling the uncertainty in the measurement processes constituting the dosimetry chain that are involved in internal absorbed dose calculations. The starting point is the basic model for absorbed dose in a site of interest as the product of the cumulated activity and a dose factor. In turn, the cumulated activity is given by the area under a time-activity curve derived from a time sequence of activity values. Each activity value is obtained in terms of a count rate, a calibration factor and a recovery coefficient (a correction for partial volume effects). The method to determine the recovery coefficient and the dose factor, both of which are dependent on the size of the volume of interest (VOI), are described. Consideration is given to propagating estimates of the quantities concerned and their associated uncertainties through the dosimetry chain to obtain an estimate of mean absorbed dose in the VOI and its associated uncertainty. This approach is demonstrated in a clinical example.

摘要

提出了一个框架，用于对构成内部吸收剂量计算的剂量学链中测量过程的不确定性进行建模。该框架的起点是感兴趣部位吸收剂量的基本模型，即累积活度与剂量系数的乘积。反过来，累积活度由从一系列时间活度值得出的时间-活度曲线下的面积给出。每个活度值都是根据计数率、校准系数和恢复系数（对部分体积效应的修正）来确定的。描述了确定恢复系数和剂量系数的方法，这两个系数都取决于感兴趣体积（VOI）的大小。考虑通过剂量学链传播相关量及其相关不确定性的估计值，以获得 VOI 中平均吸收剂量及其相关不确定性的估计值。该方法在临床实例中得到了验证。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ca/6208822/49e5b2ae7b07/259_2018_4136_Fig12_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ca/6208822/26ae25695eb1/259_2018_4136_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ca/6208822/54a6cae9c88e/259_2018_4136_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ca/6208822/bd7acbc79b1d/259_2018_4136_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ca/6208822/4d3eb8be907e/259_2018_4136_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ca/6208822/c22f0ecd2b59/259_2018_4136_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ca/6208822/d42eefcd4b86/259_2018_4136_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ca/6208822/da5a8f26f495/259_2018_4136_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ca/6208822/9f442e11f5d6/259_2018_4136_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ca/6208822/bca87ca22df5/259_2018_4136_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ca/6208822/dac11143eacb/259_2018_4136_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ca/6208822/73da66d8fd82/259_2018_4136_Fig11_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ca/6208822/49e5b2ae7b07/259_2018_4136_Fig12_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ca/6208822/26ae25695eb1/259_2018_4136_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ca/6208822/54a6cae9c88e/259_2018_4136_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ca/6208822/bd7acbc79b1d/259_2018_4136_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ca/6208822/4d3eb8be907e/259_2018_4136_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ca/6208822/c22f0ecd2b59/259_2018_4136_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ca/6208822/d42eefcd4b86/259_2018_4136_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ca/6208822/da5a8f26f495/259_2018_4136_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ca/6208822/9f442e11f5d6/259_2018_4136_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ca/6208822/bca87ca22df5/259_2018_4136_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ca/6208822/dac11143eacb/259_2018_4136_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ca/6208822/73da66d8fd82/259_2018_4136_Fig11_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ca/6208822/49e5b2ae7b07/259_2018_4136_Fig12_HTML.jpg

相似文献

1
EANM practical guidance on uncertainty analysis for molecular radiotherapy absorbed dose calculations.EANM 实践指南：分子放疗吸收剂量计算中的不确定性分析。
Eur J Nucl Med Mol Imaging. 2018 Dec;45(13):2456-2474. doi: 10.1007/s00259-018-4136-7. Epub 2018 Sep 14.
2
Uncertainty analysis of tumour absorbed dose calculations in molecular radiotherapy.分子放射治疗中肿瘤吸收剂量计算的不确定性分析
EJNMMI Phys. 2020 Oct 12;7(1):63. doi: 10.1186/s40658-020-00328-5.
3
Selective Internal Radiation Therapy With Yttrium-90 Glass Microspheres: Biases and Uncertainties in Absorbed Dose Calculations Between Clinical Dosimetry Models.钇-90玻璃微球选择性内放射治疗：临床剂量测定模型间吸收剂量计算中的偏差与不确定性
Int J Radiat Oncol Biol Phys. 2016 Nov 15;96(4):888-896. doi: 10.1016/j.ijrobp.2016.07.021. Epub 2016 Jul 27.
4
4-Step renal dosimetry dependent on cortex geometry applied to 90Y peptide receptor radiotherapy: evaluation using a fillable kidney phantom imaged by 90Y PET.基于皮质几何形状的 4 步肾剂量学在 90Y 肽受体放射治疗中的应用：使用可填充的肾脏模型和 90Y PET 成像进行评估。
J Nucl Med. 2010 Dec;51(12):1969-73. doi: 10.2967/jnumed.110.080093. Epub 2010 Nov 15.
5
Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software.使用¹²⁴I正电子发射断层显像（PET）和三维体内剂量测定法（3D-ID）软件进行¹³¹I甲状腺癌治疗的个体化剂量测定。
J Nucl Med. 2004 Aug;45(8):1366-72.
6
Hepatic structural dosimetry in (90)Y microsphere treatment: a Monte Carlo modeling approach based on lobular microanatomy.基于小叶微解剖的 (90)Y 微球治疗中肝脏结构剂量学：蒙特卡罗建模方法。
J Nucl Med. 2010 Feb;51(2):301-10. doi: 10.2967/jnumed.109.069278. Epub 2010 Jan 15.
7
Linear Boltzmann equation solver for voxel-level dosimetry in radiopharmaceutical therapy: Comparison with Monte Carlo and kernel convolution.用于放射性药物治疗体素水平剂量学的线性 Boltzmann 方程求解器：与蒙特卡罗和核卷积的比较。
Med Phys. 2024 Aug;51(8):5604-5617. doi: 10.1002/mp.16996. Epub 2024 Mar 4.
8
Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs.用（90）Y标记的生长抑素类似物进行肽受体放射性核素治疗的实用剂量测定法。
J Nucl Med. 2005 Jan;46 Suppl 1:92S-8S.
9
A dosimetric treatment planning strategy in radioembolization of hepatocarcinoma with 90Y glass microspheres.一种使用90Y玻璃微球进行肝癌放射性栓塞治疗的剂量学治疗计划策略。
Q J Nucl Med Mol Imaging. 2012 Dec;56(6):503-8.
10
On the use of the absorbed depth-dose measurements in the beam calibration of a surface electronic high-dose-rate brachytherapy unit, a Monte Carlo-based study.基于蒙特卡罗的表面电子高剂量率近距离治疗单位束流校准中吸收深度剂量测量的应用研究。
Med Phys. 2020 Feb;47(2):693-702. doi: 10.1002/mp.13920. Epub 2019 Dec 4.

引用本文的文献

1
Dosimetric study on radioembolization with 166Ho poly L-lactic acid microspheres: dead time effects on prediction power.166Ho聚L-乳酸微球放射性栓塞的剂量学研究：死时间对预测能力的影响。
EJNMMI Phys. 2025 Jul 3;12(1):64. doi: 10.1186/s40658-025-00779-8.
2
Comparison of tumour segmentation methods for dosimetry in [Lu]Lu-PSMA I&T treated patients with metastatic castration resistant prostate cancer.[镥]镥-PSMA I&T治疗的转移性去势抵抗性前列腺癌患者剂量测定中肿瘤分割方法的比较。
EJNMMI Phys. 2025 Jul 1;12(1):62. doi: 10.1186/s40658-025-00772-1.
3
Establishing measurement traceability for quantitative SPECT imaging.

本文引用的文献

1
Whole-remnant and maximum-voxel SPECT/CT dosimetry in I-NaI treatments of differentiated thyroid cancer.分化型甲状腺癌碘-碘化钠治疗中全残留和最大体素SPECT/CT剂量测定法
Med Phys. 2016 Oct;43(10):5279-5287. doi: 10.1118/1.4961742.
2
Optimized Peptide Amount and Activity for ⁹⁰Y-Labeled DOTATATE Therapy.优化 ⁹⁰Y 标记 DOTATATE 治疗的肽用量和活性。
J Nucl Med. 2016 Apr;57(4):503-8. doi: 10.2967/jnumed.115.164699. Epub 2015 Dec 17.
3
Uncertainty propagation for SPECT/CT-based renal dosimetry in (177)Lu peptide receptor radionuclide therapy.
建立定量单光子发射计算机断层显像（SPECT）成像的测量溯源性。
EJNMMI Phys. 2025 Jun 23;12(1):58. doi: 10.1186/s40658-025-00778-9.
4
Non-linear mixed-effects modelling and population-based model selection for I kinetics in benign thyroid disease.良性甲状腺疾病中碘动力学的非线性混合效应建模与基于群体的模型选择
EJNMMI Phys. 2025 Apr 8;12(1):37. doi: 10.1186/s40658-025-00735-6.
5
Blood and bone marrow dosimetry for thyroid cancer patients prepared with rhTSH injection.重组人促甲状腺素注射剂制备的甲状腺癌患者的血液和骨髓剂量测定
Ann Nucl Med. 2025 Jul;39(7):676-686. doi: 10.1007/s12149-025-02042-7. Epub 2025 Apr 5.
6
Mathematical modeling in radiotherapy for cancer: a comprehensive narrative review.癌症放射治疗中的数学建模：一项全面的叙述性综述。
Radiat Oncol. 2025 Apr 4;20(1):49. doi: 10.1186/s13014-025-02626-7.
7
Accuracy and precision analyses of single-time-point dosimetry utilising physiologically-based pharmacokinetic modelling and non-linear mixed-effects modelling.利用基于生理的药代动力学模型和非线性混合效应模型对单时间点剂量测定法进行准确性和精密度分析。
EJNMMI Phys. 2025 Mar 26;12(1):26. doi: 10.1186/s40658-025-00726-7.
8
Towards harmonized holmium-166 SPECT image quality for dosimetry: a multi-center, multi-vendor study.迈向用于剂量测定的统一钬-166单光子发射计算机断层扫描（SPECT）图像质量：一项多中心、多供应商研究。
EJNMMI Phys. 2025 Mar 19;12(1):24. doi: 10.1186/s40658-025-00733-8.
9
On the reduction of imaging time-points for dosimetry in radionuclide therapy.关于减少放射性核素治疗中剂量测定的成像时间点
EJNMMI Phys. 2025 Feb 6;12(1):14. doi: 10.1186/s40658-025-00721-y.
10
MIRD Pamphlet No. 32: A MIRD Recovery Coefficient Model for Resolution Characterization and Shape-Specific Partial-Volume Correction.医学内照射剂量学会第32号手册：用于分辨率表征和特定形状部分容积校正的医学内照射剂量学会恢复系数模型
J Nucl Med. 2025 Mar 3;66(3):457-465. doi: 10.2967/jnumed.124.268520.
基于SPECT/CT的（177）镥肽受体放射性核素治疗中肾脏剂量测定的不确定性传播
Phys Med Biol. 2015 Nov 7;60(21):8329-46. doi: 10.1088/0031-9155/60/21/8329. Epub 2015 Oct 12.
4
The NUKDOS software for treatment planning in molecular radiotherapy.用于分子放射治疗治疗计划的NUKDOS软件。
Z Med Phys. 2015 Sep;25(3):264-74. doi: 10.1016/j.zemedi.2015.01.001. Epub 2015 Mar 17.
5
MIRD pamphlet No. 24: Guidelines for quantitative 131I SPECT in dosimetry applications.MIRD 简报第 24 号：用于剂量测定应用的定量 131I SPECT 指南。
J Nucl Med. 2013 Dec;54(12):2182-8. doi: 10.2967/jnumed.113.122390. Epub 2013 Oct 15.
6
Molecular radiotherapy: the NUKFIT software for calculating the time-integrated activity coefficient.分子放疗：用于计算时间积分活度系数的 NUKFIT 软件。
Med Phys. 2013 Oct;40(10):102504. doi: 10.1118/1.4820367.
7
A review of partial volume correction techniques for emission tomography and their applications in neurology, cardiology and oncology.发射型计算机断层成像中部分容积校正技术的回顾及其在神经病学、心脏病学和肿瘤学中的应用。
Phys Med Biol. 2012 Nov 7;57(21):R119-59. doi: 10.1088/0031-9155/57/21/R119. Epub 2012 Oct 16.
8
EANM Dosimetry Committee guidance document: good practice of clinical dosimetry reporting.EANM 剂量学委员会指导文件：临床剂量报告的良好实践。
Eur J Nucl Med Mol Imaging. 2011 Jan;38(1):192-200. doi: 10.1007/s00259-010-1549-3. Epub 2010 Aug 27.
9
Radioimmunotherapy with anti-CD66 antibody: improving the biodistribution using a physiologically based pharmacokinetic model.放射性免疫治疗用抗 CD66 抗体：使用基于生理学的药代动力学模型改善生物分布。
J Nucl Med. 2010 Mar;51(3):484-91. doi: 10.2967/jnumed.109.067546. Epub 2010 Feb 11.
10
Comparing time activity curves using the Akaike information criterion.比较使用赤池信息量准则的时间活动曲线。
Phys Med Biol. 2009 Nov 7;54(21):N501-7. doi: 10.1088/0031-9155/54/21/N01. Epub 2009 Oct 9.